Avitide Eyes 2019 Profitability with Series E Financing

Avitide, a manufacturer and supplier of molecule-specific biopharmaceutical affinity purification solutions, said today it has raised an undisclosed amount in Series E financing.Avitide said it will use the proceeds to fund ongoing operations, with the goal of becoming profitable by 2019.The company focuses on delivering high-yield, high-purity, molecule-specific affinity resins on demand in three months or less. Avitide’s proprietary affinity separation technology is designed to enable it